Recombinant human interferon beta in relapsing-remitting multiple sclerosis: A review of the major clinical trials

European Journal of Neurology

Volumn 7, Issue 4, 2000, Pages 369-380

  Chofflon, M ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Early treatment; Efficacy; Expanded disability status scale; Interferon beta 1a; Interferon beta 1b; Magnetic resonance imaging; Multiple sclerosis; Progression

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; PLACEBO; RECOMBINANT BETA INTERFERON;

ADULT; BRAIN INJURY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DOSE RESPONSE; DRUG TOLERANCE; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; INJECTION PAIN; MALE; META ANALYSIS; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW;

CLINICAL TRIALS; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 0034457743     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1331.2000.00057.x     Document Type: Review

References (49)

1. Inhibition of passive localized experimental allergic encephalomyelitis by interferon
2. Pharmacokinetics and pharmacodynamics of interferon beta-1a (IFNβ-1a) in healthy volunteers after intravenous, subcutaneous or intramuscular administration
3. Clinical results and outcome measures from the multiple sclerosis PRISMS study
4. Interferon-beta is a potent promoter of nerve growth factor production by astrocytes
5. Treatment and management of multiple sclerosis
6. Evidence of early axonal damage in patients with multiple sclerosis
7. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis
8. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: A follow-up study
9. Interferonβ treatment for multiple sclerosis
10. Adherence to injection therapy in multiple sclerosis
11. Treatment of multiple sclerosis with the IFN-βs: Comparing risks and benefits
12. Selective inhibition of human glial inducible nitric oxide synthase by interferon-beta: Implications for multiple sclerosis
13. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
14. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial
15. Neutralizing antibodies during treatment with interferon beta-1b
16. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
17. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: Pilot study analysis and six-year follow-up
18. Rating neurological impairment in multiple sclerosis: An expanded disability status scale (EDSS)
19. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosis
20. 'Summary measure' statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis
21. Immunoregulatory effects of interferon-beta and interacting cytokines on human vascular endothelial cells. Implications for multiple sclerosis autoimmune diseases
22. Bioavailability of recombinant human interferon-βla after intramuscular and subcutaneous administration
23. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis
24. The prognostic value of brain MRI in clinically isolated syndromes of the CNS
25. Evidence of interferon β-1a dose response in relapsing-remitting MS: The OWIMS study
26. New and old treatments for multiple sclerosis
27. Treatment of multiple sclerosis with gamma interferon: Exacerbations associated with activation of the immune system
28. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial
29. High dose subcutaneous interferon β1a is efficacious in transitional multiple sclerosis, a group at high risk of progression
30. Magnetic resonance imaging changes with recombinant interferon-β-1a: A short-term study in relapsing-remitting multiple sclerosis
31. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing-remitting multiple sclerosis
32. Interferons in the treatment of multiple sclerosis. Do they prevent the progression of the disease?
33. Influence of interferon β-1a dose frequency on PBMC cytokine secretion and biological effect markers
34. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis
35. Interferon beta induces interleukin-10 expression: Relevance to multiple sclerosis
36. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis
37. Structural and functional differences between glycosylated and nonglycosylated forms of human interferon-β
38. Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis
39. Interferon beta-1b decreases the migration of T lymphocytes in vitro: Effects on metalloprotease-9
40. Axonal transection in the lesions of multiple sclerosis
41. Neurodegeneration in multiple sclerosis: Relationship to neurological disability
42. Recombinant interferon-β-1a. A review of its therapeutic efficacy in relapsing-remitting multiple sclerosis
43. The natural history of multiple sclerosis: A geographically-based study. 2. Predictive value of the early clinical course
44. Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and Avonex
45. Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-beta
46. Interferon beta inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis